Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05716295

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors — ORCHID-1  

Advanced or Metastatic Solid Tumors Clinical Trial

Official title:
A Phase 1/2, Open-Label, Multicenter Study of MDK-703 as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1)

Clinical Trial Summary

This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.

Clinical Trial Description

This is a Phase 1/2, open-label, multicenter, dose escalation and dose expansion study evaluating MDK-703 in adult study participants with advanced or metastatic solid tumors. This study will initially commence with dose escalation to evaluate the safety/tolerability of MDK-703 as a monotherapy and in combination with other cancer therapies. Once the monotherapy and/or combination therapy maximum tolerated dose (MTD), optimal biological dose (OBD), and/or recommended dose (RD) has been determined, then dose expansion of MDK-703 may commence in select populations of interest. The study will also evaluate the anti-tumor activity and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of MDK-703 as a monotherapy and in combination with other cancer therapies. ;

Study Design

Related Conditions & MeSH terms

  • Advanced or Metastatic Solid Tumors
  • Neoplasms
Clinical Trial Details
NCT number NCT05716295
Study type Interventional
Source Medikine, Inc.
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date February 8, 2023
Completion date April 30, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05017012 - A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18) Phase 1
Completed NCT02261532 - A Phase I Study of TAS-102 in Solid Tumors Phase 1
Completed NCT00748553 - A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer Phase 1/Phase 2
Completed NCT03248843 - A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Terminated NCT04003623 - Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) Phase 2
Terminated NCT05496595 - DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT01928394 - A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Terminated NCT01506934 - A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03730337 - Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04586270 - A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer Phase 1
Recruiting NCT06248411 - A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06389526 - A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03665285 - A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05957081 - Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 Phase 1
Active, not recruiting NCT03316638 - A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Terminated NCT01355302 - E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer Phase 1/Phase 2
Completed NCT01014429 - Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06074497 - A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT04866134 - A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors Phase 1/Phase 2